Clinical Trial Update: Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describes neoadjuvant sasanlimab with radiation as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Sasanlimab (sasanlimab)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Urothelial Carcinoma Bladder | Phase 2 | Status: ACTIVE_NOT_RECRUITING